Fig. 2From: Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysisForest plot of the association between CDH13 methylation and bladder cancer from a fixed-effects model, including 8 studies with 920 bladder cancer patients and 265 controls, OR = 21.71, 95 % CI: 9.83–47.94, P < 0.001Back to article page